Terms: = Endocrine gland cancer AND EPAS1, MOP2, 2034, ENSG00000116016, PASD2, HIF2A, Q99814 AND Treatment
26 results:
1. Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab.
Verleye L; Castanares-Zapatero D; Devos C; De Gendt C; Silversmit G; Van Damme N; Hulstaert F; Thiry N; Neyt M
Int J Gynecol Cancer; 2023 Apr; 33(4):543-548. PubMed ID: 36604121
[TBL] [Abstract] [Full Text] [Related]
2. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
[TBL] [Abstract] [Full Text] [Related]
4. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
[TBL] [Abstract] [Full Text] [Related]
5. Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Kamihara J; Hamilton KV; Pollard JA; Clinton CM; Madden JA; Lin J; Imamovic A; Wall CB; Wassner AJ; Weil BR; Heeney MM; Vargas SO; Kaelin WG; Janeway KA; Perini RF; Zojwalla NJ; Voss SD; DuBois SG
N Engl J Med; 2021 Nov; 385(22):2059-2065. PubMed ID: 34818480
[TBL] [Abstract] [Full Text] [Related]
6. Personalized Management of Pheochromocytoma and Paraganglioma.
Nölting S; Bechmann N; Taieb D; Beuschlein F; Fassnacht M; Kroiss M; Eisenhofer G; Grossman A; Pacak K
Endocr Rev; 2022 Mar; 43(2):199-239. PubMed ID: 34147030
[TBL] [Abstract] [Full Text] [Related]
7. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
[TBL] [Abstract] [Full Text] [Related]
8. The VHL/HIF Axis in the Development and treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract] [Full Text] [Related]
9. METTL3 potentiates resistance to cisplatin through m
Wei J; Yin Y; Zhou J; Chen H; Peng J; Yang J; Tang Y
J Cell Mol Med; 2020 Oct; 24(19):11366-11380. PubMed ID: 32857912
[TBL] [Abstract] [Full Text] [Related]
10. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
Cabasag CJ; Butler J; Arnold M; Rutherford M; Bardot A; Ferlay J; Morgan E; Møller B; Gavin A; Norell CH; Harrison S; Saint-Jacques N; Eden M; Rous B; Nordin A; Hanna L; Kwon J; Cohen PA; Altman AD; Shack L; Kozie S; Engholm G; De P; Sykes P; Porter G; Ferguson S; Walsh P; Trevithick R; Tervonen H; O'Connell D; Bray F; Soerjomataram I
Gynecol Oncol; 2020 Apr; 157(1):234-244. PubMed ID: 32005583
[TBL] [Abstract] [Full Text] [Related]
11. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract] [Full Text] [Related]
12. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study.
Huang L; Jansen L; Balavarca Y; Babaei M; van der Geest L; Lemmens V; Van Eycken L; De Schutter H; Johannesen TB; Primic-Žakelj M; Zadnik V; Besselink MG; Schrotz-King P; Brenner H
BMC Med; 2018 Aug; 16(1):125. PubMed ID: 30126408
[TBL] [Abstract] [Full Text] [Related]
13. Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic cancer Metastasis.
Wang X; Luo G; Zhang K; Cao J; Huang C; Jiang T; Liu B; Su L; Qiu Z
Cancer Res; 2018 Aug; 78(16):4586-4598. PubMed ID: 29880482
[TBL] [Abstract] [Full Text] [Related]
14. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract] [Full Text] [Related]
15. HIF-3α Promotes Metastatic Phenotypes in Pancreatic cancer by Transcriptional Regulation of the RhoC-ROCK1 Signaling Pathway.
Zhou X; Guo X; Chen M; Xie C; Jiang J
Mol Cancer Res; 2018 Jan; 16(1):124-134. PubMed ID: 28928287
[TBL] [Abstract] [Full Text] [Related]
16. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract] [Full Text] [Related]
17. Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.
Pang Y; Yang C; Schovanek J; Wang H; Bullova P; Caisova V; Gupta G; Wolf KI; Semenza GL; Zhuang Z; Pacak K
Oncotarget; 2017 Apr; 8(14):22313-22324. PubMed ID: 28423608
[TBL] [Abstract] [Full Text] [Related]
18. PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.
Gupta G; Pacak K;
Endocr Pract; 2017 Jun; 23(6):690-704. PubMed ID: 28332883
[TBL] [Abstract] [Full Text] [Related]
19. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract] [Full Text] [Related]
20. PLGA/poloxamer nanoparticles loaded with epas1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K
Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594
[TBL] [Abstract] [Full Text] [Related]
[Next]
